Thrombospondin-1/HIV-1 Tat protein interaction: Modulation of the biological activity of extracellular Tat

FASEB Journal

Volumn 14, Issue 13, 2000, Pages 1917-1930

  Rusnati, M ^a   Taraboletti, G ^b   Urbinati, C ^a   Tulipano, G ^a   Giuliani, R ^a   Molinari Tosatti, M P ^a   Sennino, B ^a   Giacca, M ^c   Tyagi, M ^c   Albini, A ^d   Noonan, D ^d   Giavazzi, R ^b   Presta, M ^a,e  

^a UNIVERSITY OF BRESCIA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e Via Valsabbina 19 ^*  (Italy)

Author keywords

AIDS; Angiogenesis; Extracellular matrix; Oncogenesis

Indexed keywords

GLUTATHIONE TRANSFERASE; GLYCOPROTEIN; PROTEOHEPARAN SULFATE; THROMBOSPONDIN 1; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOGENESIS; ANIMAL CELL; ARTICLE; AUTOCRINE EFFECT; BINDING AFFINITY; CARCINOGENESIS; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0033820634     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.99-0902com     Document Type: Article

References (82)

1. Isolation of a T-lymphotrophic retrovirus from a patient at risk for acquired immunodeficency syndrome
2. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS
3. Cloning and functional analysis of multiply spliced mRNA species of human immunodeficency virus
4. Release, uptake, and effects of extracellular human immunodeficency virus type 1 tat protein on cell growth and viral transcription
5. Endocytosis and targeting of exogenous HIV-1 Tat protein
6. Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumor cell lines derived from BK virus/Tat-transgenic mice
7. Cerebral glial tumors and human immunodeficiency virus-1 infection.More than a coincidental association
8. Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1
9. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice
10. Liver cancer in transgenic mice carrying the human immunodeficiency virus tat gene
11. Systemic expression of HIV-1 Tat gene in transgenic mice induces endothelial proliferation and tumors of different histotypes
12. A novel approach to protein-protein interaction: Complex formation between the p53 tumor suppressor and the HIV Tat protein
13. An RGD containing peptide from HIV-1 Tat-(65-80) modulates protooncogene expression in human bronchoalveolar carcinoma cell line. A549
14. Human immunodeficiency virus type 1 tat gene enhances human papillomavirus early gene expression
15. The HIV Tat gene transforms human keratinocytes
16. HIV type 1 extracellular Tat protein stimulates growth and protects cells of BK Virus/Tat transgenic mice from apoptosis
17. Tat-expressing Jurkat cells show an increased resistance to different apoptotic stimuli, including acute human immunodeficiency virus-type 1 (HIV-1) infection
18. The Tat protein of human immunodeficency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence
19. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells
20. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: Inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2
21. Kaposi's sarcoma pathogenesis: A link between immunology and tumor biology
22. The enigmas of Kaposi's sarcoma
23. Tat-human immunodeficiency virus-1 induces human monocyte chemotaxis by activation of vascular endothelial growth factor receptor-1
24. HIV-1 Tat protein mimicry of chemokines
25. Tat protein from HIV-1 activates MAP kinase in granular neurons and glial cells from rat cerebellum
26. HIV-1 Tat induces tyrosine phosphorylation of p125FAK and its association with phosphoinositide 3-kinase in PC12 cells
27. Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells
28. Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells
29. Interaction of HIV-1 Tat protein with heparin: Role of the backbone structure, sulfation, and size
30. The basic domain in HIV-1 Tat protein as a target for polysulfated heparin-mimicking extracellular Tat antagonists
31. Multiple interaction of HIV-1 Tat protein with size-defined heparin oligosaccharides
32. HIV-1 Tat protein is a heparin binding angiogenic growth factor
33. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region
34. Fibronectin modulates the effects of HIV-1 Tat on the growth of routine Kaposi's sarcoma-like cells through the down-regulation of tyrosine phosphorylation
35. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2
36. Physiology of thrombospondin
37. Thrombospondins
38. Diversity of function is inherent in matricellular proteins: An appraisal of thrombospondin 1
39. Expression and initial characterization of a recombinant human thrombospondin heparin binding domain
40. Heparin-binding domain, type 1 and type 2 repeats of thrombospondin mediate its interaction with human breast cancer cells
41. Interactions of thrombospondin with sulfated glycolipids and proteoglycans of human melanoma cells
42. Cell-associated proteoheparan sulfate mediates binding and uptake of thrombospondin in cultured porcine vascular endothelial cells
43. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: A potential angiogenesis regulatory factor
44. Thrombospondin induces glomerular mesangial cell adhesion and migration
45. Matrix-bound thrombospondin promotes angiogenesis in vitro
46. Thrombospondin (TSP) and transforming growth factor beta I (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro
47. Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice
48. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis
49. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization
50. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro
51. Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serumand anchorage-independent NIH 3T3 cells
52. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1
53. The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor
54. Scatter factor brads to thrombospondin and other extracellular matrix components
55. Transforming growth factor-beta complexes with thrombospondin
56. Interaction of platelet-derived growth factor with thrombospondin 1
57. Thrombospondin 1 as an enzyme inhibitor
58. Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat induced angiogenesis and is poorly expressed in KS lesions
59. Localization of the hemagglutinating activity of platelet thrombospondin to a 140 000-dalton thermolytic fragment
60. Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1
61. HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter
62. The attractions of proteins for small molecules and ions
63. Expression and characterization of the trans-activator of HTLV-III/LAV virus
64. Promotion of tumor metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/Tat transgenic mice
65. Hemangioma formation and angiogenesis induced in chick embryo chorioallantoic membrane by endothelial cells overexpressing basic fibroblast growth factor (FGF-2)
66. Monoclonal antibodies specific for endothelial cells of mouse blood vessels.Their application in the identification of adult and embryonic endothelium
67. HIV-1 Tat: Structure and function
68. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans
69. The interaction of the transforming growth factor-beta with heparin/heparan sulfate is isoform-specific
70. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells
71. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas
72. Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis
73. Plasma thrombospondin as an indicator of intravascular platelet activation in patients with vasculitis
74. Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection
75. Expression of adhesion molecules in endemic and epidemic Kaposi's sarcoma
76. HIV-1 Tat protein as a potential AIDS vaccine
77. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: A rationale for the use of Tat toxoid as an HIV-1 vaccine
78. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
79. A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition
80. A Tat antagonist inhibits HIV-1 induction in naturally infected and experimentally infected T cells
81. Identification of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120: Relationship to HIV-1-specific inhibitory factors in human saliva
82. Endogenous mucosal antiviral factors of the oral cavity